Eralop Study: Hair Regrowth After Adjuvant Fec-Docetaxel Chemotherapy For Early Breast Cancer In The Real Life

e12014 Background: During 2008 we have collected one hundred observations of persisting alopecia (PA). The FEC 100-docetaxel 100 mg/msq regimen was mostly concerned. We therefore decided to evaluate exact incidence of this relevant side effect through women points of view. Methods: ERALOP is a retrospective study using a self-questionnaire targeting patients (pts) treated with this sequential regimen from 2008 to 2009. The primary objective was to estimate the incidence of a PA at 6 months after last course of docetaxel with CTCAE 4.0 classification: grade 1: hair loss of up to 50% not obvious from a distance, a different hair style may be required to cover the hair loss, grade 2: hair loss u003e 50% with a psychosocial impact. The sample size calculation of 635 patients took into account: PA incidence of 3.2% (TAC regimen), precision of 0.015, α risk at 0.05, 20% patients lost for follow up. ERALOP study was approved by local ethic comitee. Results: from July 2012 to October 2012, 829 pts received a self-que...